A1 Refereed original research article in a scientific journal
Outcomes after completing growth-friendly surgical treatment for early-onset scoliosis in patients with skeletal dysplasia
Authors: Saarinen, Antti J.; Sponseller, Paul; Thompson, George H.; White, Klane K.; Emans, John; Cahill, Patrick J.; Hwang, Steven; Helenius, Ilkka
Publisher: British Editorial Society of Bone & Joint Surgery
Publication year: 2024
Journal: Bone and Joint Journal
Journal name in source: The bone & joint journal
Journal acronym: Bone Joint J
Volume: 106-B
Issue: 6
First page : 596
Last page: 602
ISSN: 2049-4394
eISSN: 2049-4408
DOI: https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-1417.R2
Web address : https://boneandjoint.org.uk/Article/10.1302/0301-620X.106B6.BJJ-2023-1417.R2
Aims: The aim of this study was to compare outcomes after growth-friendly treatment for early-onset scoliosis (EOS) between patients with skeletal dysplasias versus those with other syndromes.
Methods: We retrospectively identified 20 patients with skeletal dysplasias and 292 with other syndromes (control group) who had completed surgical growth-friendly EOS treatment between 1 January 2000 and 31 December 2018. We compared radiological parameters, complications, and health-related quality of life (HRQoL) at mean follow-up of 8.6 years (SD 3.3) in the dysplasia group and 6.6 years (SD 2.6) in the control group.
Results: Mean major curve correction per patient did not differ significantly between the dysplasia group (43%) and the control group (28%; p = 0.087). Mean annual spinal height increase was less in the dysplasia group (9.3 mm (SD 5.1) than in the control group (16 mm (SD 9.2); p < 0.001). Mean annual spinal growth adjusted to patient preoperative standing height during the distraction period was 11% in the dysplasia group and 14% in the control group (p = 0.070). The complication rate was 1.6 times higher (95% confidence interval (CI) 1.3 to 2.0) in the dysplasia group. The following complications were more frequent in the dysplasia group: neurological injury (rate ratio (RR) 5.1 (95% CI 2.3 to 11)), deep surgical site infection (RR 2.2 (95% CI 1.2 to 4.1)), implant-related complications (RR 2.0 (95% CI 1.5 to 2.7)), and unplanned revision (RR 1.8 (95% CI 1.3 to 2.5)). Final fusion did not provide additional spinal height compared with watchful waiting (p = 0.054). There were no significant differences in HRQoL scores between the groups.
Conclusion: After growth-friendly EOS treatment, patients with skeletal dysplasias experienced a higher incidence of complications compared to those with other syndromes. Surgical growth-friendly treatment for skeletal dysplasia-associated EOS should be reserved for patients with severe, progressive deformities that are refractory to nonoperative treatment.
Funding information in the publication:
The authors disclose receipt of the following financial or material support for the research, authorship, and/or publication of this article: A. J. Saarinen has received research funding from Vappu Uuspää Foundation and Päivikki and Sakari Sohlberg Foundation.